DrugPatentWatch Database Preview
Drugs in Development Information for ASP1517
Email this page to a colleague
What is the drug development status for ASP1517?
ASP1517 is an investigational drug.
There have been 24 clinical trials for ASP1517.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2013.
The most common disease conditions in clinical trials are Anemia, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are FibroGen, Astellas Pharma Inc, and Astellas Pharma Europe B.V.
There are forty-nine US patents protecting this investigational drug and three hundred and seventy-eight international patents.
Summary for ASP1517
| US Patents | 49 |
| International Patents | 378 |
| US Patent Applications | 160 |
| WIPO Patent Applications | 83 |
| Japanese Patent Applications | 26 |
| Clinical Trial Progress | Phase 2 (2013-05-01) |
| Vendors | 77 |
Recent Clinical Trials for ASP1517
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation i | FibroGen | Phase 1 |
| A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation i | Astellas Pharma Global Development, Inc. | Phase 1 |
| Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden | AstraZeneca | Phase 3 |
Clinical Trial Summary for ASP1517
Top disease conditions for ASP1517
Top clinical trial sponsors for ASP1517
US Patents for ASP1517
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ASP1517 | Try Before You Buy | Nitrogen-containing heteroaryl compounds and methods of use thereof | FibroGen, Inc. (San Francisco, CA) | Try Before You Buy |
| ASP1517 | Try Before You Buy | Crystalline forms of a prolyl hydroxylase inhibitor | FibroGen, Inc. (San Francisco, CA) | Try Before You Buy |
| ASP1517 | Try Before You Buy | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | Try Before You Buy |
| ASP1517 | Try Before You Buy | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | Pfizer Inc. (New York, NY) | Try Before You Buy |
| ASP1517 | Try Before You Buy | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | Try Before You Buy |
| ASP1517 | Try Before You Buy | Generation of muscle lineage cells and therapeutic uses thereof | GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) | Try Before You Buy |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ASP1517
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ASP1517 | Austria | AT496033 | 2023-06-06 | Try Before You Buy |
| ASP1517 | Australia | AU2004245552 | 2023-06-06 | Try Before You Buy |
| ASP1517 | Brazil | BRPI0411055 | 2023-06-06 | Try Before You Buy |
| ASP1517 | Canada | CA2528232 | 2023-06-06 | Try Before You Buy |
| ASP1517 | China | CN102718708 | 2023-06-06 | Try Before You Buy |
| ASP1517 | China | CN102977015 | 2023-06-06 | Try Before You Buy |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
